Clik here to view.
Covidien updates on medical device, pharma split
Healthcare giant Covidien (NYSE:COV) issued updates on its long-awaited split into separate medical device and drug units and incorporated the Mallinckrodt pharmaceutical division as an independent...
View ArticleClik here to view.
William Blair boosts NxStage stake by 20% | Wall Street Beat
William Blair & Co. added 20% to its holdings in NxStage Medical (NSDQ:NXTM) last year, according to regulatory filings. The Chicago-based investment bank owned more than 3.8 million NXTM shares...
View ArticleClik here to view.
Meet the ‘New Covidien’
Covidien (NYSE:COV) said it expects to pull the trigger on the spinout of its pharmaceuticals division near the end of June and issued guidance for its new, sleeker post-spinout profile. The...
View ArticleClik here to view.
Covidien puts a bow on pharma spinout, Wall Street backs off
Covidien (NYSE:COV) today consummated the spinout of its pharmaceutical business by announcing the launch of Mallinckrodt plc (NYSE: MNK) on the New York Stock Exchange. MNK shares opened today at...
View ArticleClik here to view.
Baxter reveals plans to split pharma, medical products businesses
Baxter (NYSE:BAX) said it plans to separate its medical products and pharmaceuticals businesses into independent companies, following in the footsteps of rivals Abbott (NYSE:ABT) and Covidien...
View ArticleClik here to view.
Analyst speculates Smith & Nephew split | Medtech Wall Street news for the...
Will Smith & Nephew split up too? March 28, 2014 by Brad Perriello Smith & Nephew shares gained in London and New York today on an analyst’s speculation that the British medical device maker...
View ArticleClik here to view.
Covidien spinout Mallinckrodt to acquire Stratatech
Mallinckrodt plc (NYSE: MNK) said today that it agreed to acquire Stratatech and its StrataGraft artificial skin graft technology for an undisclosed amount. Mallinckrodt, the pharmaceuticals business...
View ArticleClik here to view.
Covidien spinout Mallinckrodt to ditch nuclear imaging biz for $690m
Former Covidien spinout Mallinckrodt plc (NYSE: MNK) said today it is selling its nuclear imaging business to IBA molecular for $690 million. U.K.-based Mallinckrodt said it is hopeful that the deal...
View ArticleClik here to view.
Mallinckrodt touts data for Ofirmev injected acetaminophen
Mallinckrodt Pharmaceuticals (NYSE:MNK) today released results from a clinical pharmacokinetic study evaluating the effect of IV morphine on the absorption of oral acetaminophen, touting the...
View ArticleClik here to view.
Mesoblast gains on A$29m investment deal with Mallinckrodt
Shares in stem cell company Mesoblast Ltd (ASX:MSB) rose 7% to A$1.51 yesterday after it said that it entered into an equity purchase agreement with US drugmaker Mallinckrodt Pharmaceuticals...
View ArticleClik here to view.
Covidien spinout Mallinckrodt closes $690m sale of nuclear imaging biz
Covidien spinout Mallinckrodt plc (NYSE:MNK) said today that it closed the $690 million sale of its nuclear imaging business to IBA Molecular. Mallinckrodt’s nuclear imaging business includes 2...
View ArticleClik here to view.
Mallinckrodt, Marathon leave industry trade group over drug pricing controversy
Marathon Pharmaceuticals reportedly withdrew from the drug industry’s lobbying group yesterday following controversy over its pricey drug, Emflaza. Pharmaceutical Research and Manufacturers of America...
View ArticleClik here to view.
Mallinckrodt faces probe over price hikes for injectable pain-killer
Sen. Claire McCaskill (D-Mo.) penned a letter to Mallinckrodt Pharmaceuticals (NYSE:MNK) last week, probing for details about the company’s pricing strategies for its injectable pain-killer, Ofirmev....
View ArticleClik here to view.
Mallinckrodt mulls sale of generics biz
Mallinckrodt Pharmaceuticals (NYSE:MNK) is reportedly considering a sale of its generic drug unit in an effort to focus its portfolio on high-margin branded drugs, according to a report from Reuters....
View ArticleClik here to view.
Mallinckrodt launches pivotal trial for StrataGraft regenerative skin graft
Mallinckrodt (NYSE:MNK) said today that it enrolled the 1st patient in the pivotal Phase III trial of its StrataGraft skin tissue graft. The study is slated to include patients with 3% to 49% total...
View ArticleClik here to view.
Mallinckrodt responds to probe into pricey injection pain-killer
Mallinckrodt Pharmaceuticals (NYSE:MNK) issued a response today to Sen. Claire McCaskill (D-Mo.) and her probe into the company’s pricing strategies for its injectable pain-killer, Ofirmev. McCaskill...
View ArticleClik here to view.
Mallinckrodt wins orphan drug status for long-acting muscular dystrophy therapy
Mallinckrodt Pharmaceuticals (NYSE:MNK) said today that the FDA granted orphan drug status to its long-acting cosyntropin acetate formulation, MNK-1411, for the treatment of Duchenne muscular...
View ArticleClik here to view.
FDA grants regenerative medicine advanced therapy status to Mallinckrodt’s...
Mallinckrodt Pharmaceuticals (NYSE:MNK) said today that its StrataGraft regenerative skin tissue won regenerative medicine advanced therapy status from the FDA. The tissue-based therapy is among the...
View ArticleClik here to view.
Mallinckrodt enrolls first infant in registry for inhaled nitric oxide gas
Mallinckrodt Pharmaceuticals (NYSE:MNK) said today that it included the first patient in its Phase IV registry evaluating the use of inhaled Inomax nitric oxide gas for premature neonates compared to...
View ArticleClik here to view.
DOJ subpoenas Mallinckrodt over opioids
Mallinckrodt Pharmaceuticals (NYSE:MNK) said yesterday that it received a subpoena from the U.S. Dept. of Justice requesting information related to its marketing practices and sales of opioids. The...
View Article
